Logo

Boehringer Ingelheim Reports Results of BI 425809 in P-II Study for Patients with Schizophrenia

Share this

Boehringer Ingelheim Reports Results of BI 425809 in P-II Study for Patients with Schizophrenia

Shots:

  • The P-II study involves assessing of BI 425809 (4 oral doses- qd) vs PBO over 12wks. treatment period in schizophrenia patients. The results are presented at the 33rd ECNP Congress
  • Results: met its 1EPs and showed improvement in cognition in stable adult schizophrenia patients. The results are being further evaluated in cognitive impairment associated with schizophrenia
  • BI 425809 is an orally administered- glycine transporter-1 inhibitor and a key component of Boehringer Ingelheim’s CNS research program. The results along with an ongoing combination P-II study of BI 425809 and adjunctive computerized cognitive training- will help determine the direction for BI 425809 in further schizophrenia research

­ Ref: Buisness wire | Image: GMP News

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions